{"id":"W4402561075","doi":"10.1016/j.annonc.2024.08.1046","title":"986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; OncoMed Pharmaceutical; European Society for Medical Oncology; AstraZeneca; Novocure; Institut National Du Cancer; FibroGen; Astellas Pharma; Eisai; Sociedad Española de Oncología Médica; BeiGene; Sierra Oncology; Fondation ARC pour la Recherche sur le Cancer; Pharmacyclics; Agios Pharmaceuticals; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; Celgene","keywords":"Medicine; Lenvatinib; Hepatocellular carcinoma; Oncology; Internal medicine; Immunotherapy; Phases of clinical research; Sorafenib; Chemotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009999684,0.001044971,0.001602405,0.0004348406,0.0002783389,0.0009456699,0.0005429237,0.0006134263,0.001995704],"category_scores_gemma":[0.0005233353,0.0004518106,0.001539275,0.0005970843,0.0005767862,0.001047904,0.0002801915,0.001936627,0.000542317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009532965,"about_ca_system_score_gemma":0.0007536407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009810925,"about_ca_topic_score_gemma":0.00359861,"domain_scores_codex":[0.9996315,0.0001621485,0.00002167283,0.00007054054,0.00004139176,0.00007275795],"domain_scores_gemma":[0.999709,0.00005210947,0.00007534576,0.00002278701,0.00001696055,0.0001238414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6614535,0.02672245,0.03338107,0.001139398,0.006651971,0.0003537123,0.0002724074,0.005303899,0.03151493,0.0003301522,0.003914749,0.2289618],"study_design_scores_gemma":[0.5100152,0.3840781,0.08581495,0.0001237684,0.004749294,0.0007020301,0.0002540226,0.002874711,0.004876211,0.000499014,0.005926569,0.0000861303],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995732,0.00214407,0.0001420336,0.0001879241,0.00005325328,0.000222172,0.0004256378,0.00003077076,0.001062128],"genre_scores_gemma":[0.9938062,0.002289871,0.0006017409,0.0003771298,0.00008542155,0.000275552,0.001263559,0.00001835552,0.001282071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001995704,"threshold_uncertainty_score":0.006916702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.071613809024952,"score_gpt":0.4218901432045754,"score_spread":0.3502763341796234,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}